Latest & greatest articles for elderly

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on elderly or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on elderly and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for elderly

1. Cannabidiol (Epidyolex) - As adjunctive therapy of seizures associated with Lennox?Gastaut syndrome (LGS) in conjunction with clobazam, for patients 2 years of age and older.

Cannabidiol (Epidyolex) - As adjunctive therapy of seizures associated with Lennox?Gastaut syndrome (LGS) in conjunction with clobazam, for patients 2 years of age and older. 1 Published 7 September 2020 1 SMC2263 cannabidiol 100mg/ml oral solution (Epidyolex®) GW Research Ltd 7 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following a full submission considered under the orphan process cannabidiol (Epidyolex ® ) is accepted for use within NHSScotland. Indication under review: for use as adjunctive therapy of seizures associated with Lennox- Gastaut syndrome, in conjunction with clobazam, for patients 2 years of age and older. In two phase III, placebo-controlled studies cannabidiol reduced drop seizure frequency in the clobazam-treated subgroup of children and adults (aged 2 to 55 years

2020 Scottish Medicines Consortium

2. Cannabidiol (Epidyolex) - As adjunctive therapy of seizures associated with  Dravet syndrome (DS) in conjunction with clobazam, for patients 2 years of age and older.

Cannabidiol (Epidyolex) - As adjunctive therapy of seizures associated with  Dravet syndrome (DS) in conjunction with clobazam, for patients 2 years of age and older. 1 Published 7 September 2020 1 SMC2262 cannabidiol 100mg/ml oral solution (Epidyolex®) GW Research Ltd 7 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission considered under the orphan process cannabidiol (Epidyolex ® ) is accepted for use within NHSScotland. Indication under review: for use as adjunctive therapy of seizures associated with Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. In two phase III, placebo-controlled studies cannabidiol reduced convulsive seizure frequency in the clobazam-treated subgroup of children (aged 2 to 18 years) with Dravet syndrome

2020 Scottish Medicines Consortium

3. Brolucizumab (Beovu) - For the treatment of neovascular (wet) age-related macular degeneration (wAMD).

Brolucizumab (Beovu) - For the treatment of neovascular (wet) age-related macular degeneration (wAMD). 1 Published 7 September 2020 1 SMC2272 brolucizumab 120mg/mL solution for injection in pre- filled syringe (Beovu®) Novartis Pharmaceutical UK Ltd 07 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland (...) . The advice is summarised as follows: ADVICE: following a full submission brolucizumab (Beovu®) is accepted for use within NHSScotland. Indication under review: in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD). Non-inferiority of brolucizumab versus another anti-vascular endothelial growth factor medicine was demonstrated for mean change in best corrected visual acuity from baseline to week 48 in two phase III studies in patients with neovascular AMD. This advice

2020 Scottish Medicines Consortium

4. Declining COVID-19 Case Fatality Rates across all ages: analysis of German data

has declined in all age groups, and the older age groups drive the overall reduction. We have that the UK case-fatality rate (CFR) has fallen substantially from its peak in April. One explanation is that, unlike in March and April, new cases are predominantly in younger people who have a better outcome. We, therefore, sought to examine trends in CFR over time to see if the fatality rate was declining across all age groups. Due to the absence of age-stratified case data in the UK (although we’re (...) 10 (week commencing 3rd March) till week 35 (week ending 31st August). In the early phase of the pandemic, deaths in Germany mirrored cases, but the recent trend is for cases to increase whilst deaths continue to decline. Crude estimates of the CFR over time show that for people aged 80 and over the average CFR was 29% up to week 18, fell to 17% in weeks 19 to 27, and for mid-July onwards the CFR was 11% – a decrease of 61%. A larger decrease is seen in the ages 60-79 with average CFR ~ 9

2020 Oxford COVID-19 Evidence Service

5. ECG predictors of cardiac arrhythmias in older adults with syncope

ECG predictors of cardiac arrhythmias in older adults with syncope Prognosis Critical Appraisal Form Citation: Nishijima, D. K., Lin, A. L., Weiss, R. E., Yagapen, A. N., Malveau, S. E., Adler, D. H., . . . Sun, B. C. (2018). ECG Predictors of Cardiac Arrhythmias in Older Adults With Syncope. Annals of Emergency Medicine, 71(4)..2017.11.014 Methodology: Prospective convenience sample of 11 academic ED’s in the USA. Authors attempted to assess patients over the age of 60 with a complaint (...) and may overrepresent those with more serious overall outcomes of 9%. Which is higher than generally reported in syncope data of serious adverse events of 3-5% A majority of their patients were admitted to an observation unit and it is unclear what the mean period of observation was or what their observation protocol was. In some ways yes- obviously we see plenty of elderly patients, although the number of white people do seem over- represented. Also given this was largely performed in large cities

2020 Emergency Medicine Journal Club

6. Nifurtimox (Lampit) - To treat Chagas disease in certain pediatric patients younger than age 18

Nifurtimox (Lampit) - To treat Chagas disease in certain pediatric patients younger than age 18 Drug Approval Package: LAMPIT U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LAMPIT Company: Bayer HealthCare Pharmaceuticals, Inc. Application Number: 213464 Approval Date: 08/6/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application (...) Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 31, 2020 Vision impaired people having problems accessing certain pages of a PDF file may call (301) 796-3634 for assistance. Note: Documents in PDF format require the . Note: If you need help accessing information in different file formats, see . Language Assistance Available: | | | | | | | | | | | | | | | FDA Popular Content Product Areas

2020 FDA - Drug Approval Package

7. Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial Full Text available with Trip Pro

of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. 3 Department of Kinesiology, University of Waterloo and Schlegel-UW Research Institute for Aging, Waterloo, Canada. 4 School of Health and Life Sciences, Institute of Applied Health Research, Centre for Living, Glasgow Caledonian University, Glasgow, UK. PMID: 32682416 PMCID: DOI: Free PMC article Item in Clipboard Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance (...) fractures, but few studies have investigated the effect of exercise on outcomes of importance for this population. Post-intervention effects of exercise are even less studied. The objective of this study was to evaluate habitual walking speed and other health-related outcomes after cessation of a 3-month exercise intervention. Methods: This follow-up study was conducted 3 months post-intervention of a randomised controlled trial. A total of 149 community-dwelling Norwegian women aged 65 years or older

2020 EvidenceUpdates

8. Hospital Elder Life Program in Long-Term Care (HELP-LTC): A Cluster Randomized Controlled Trial

York, USA. 7 Aging Brain Center, Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA. 8 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. PMID: 32710658 DOI: Item in Clipboard Hospital Elder Life Program in Long-Term Care (HELP-LTC): A Cluster Randomized Controlled Trial Kenneth S Boockvar et al. J Am Geriatr Soc . 2020 . Show details Display options Display options Format J Am Geriatr Soc Actions . 2020 (...) College, New York, New York, USA. 7 Aging Brain Center, Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA. 8 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. PMID: 32710658 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Background/objectives: The Hospital Elder Life Program (HELP) has been shown to prevent delirium in hospitalized older adults. The objective

2020 EvidenceUpdates

9. Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial

-text links Cite Display options Display options Format Abstract Importance: Urinary incontinence is one of the most prevalent health concerns experienced by older women (aged ≥60 years). Individual pelvic floor muscle training (PFMT) is the recommended first-line treatment for stress or mixed urinary incontinence in women, but human and financial resources limit its delivery. Whether group-based PFMT performs as well as individual PFMT in this population remains unclear. Objective: To assess (...) the efficacy of group-based PFMT relative to individual PFMT for urinary incontinence in older women. Design, setting, and participants: The Group Rehabilitation or Individual Physiotherapy (GROUP) study is a single-blind, randomized, noninferiority trial conducted in 2 Canadian research centers, from July 1, 2012, to June 2, 2018. A total of 362 community-dwelling women aged 60 years or older with symptoms of stress or mixed urinary incontinence were enrolled. Interventions: After an individual session

2020 EvidenceUpdates

10. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial

people using aspirin. We calculated the incidence, risk factors and absolute risk using data from a large randomised, controlled trial. Design: Data were extracted from an aspirin versus placebo primary prevention trial conducted throughout 2010-2017 ('ASPirin in Reducing Events in the Elderly (ASPREE)', n=19 114) in community-dwelling persons aged ≥70 years. Clinical characteristics were collected at baseline and annually. The endpoint was major GI bleeding that resulted in transfusion (...) City, Iowa, USA. 9 Division of Geriatrics, Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, USA. 10 Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, Minnesota, USA. PMID: 32747412 DOI: Item in Clipboard Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial Suzanne E Mahady et al. Gut . 2020 . Show details Display

2020 EvidenceUpdates

11. Effect of High-Dose Erythropoietin on Blood Transfusions in Extremely Low Gestational Age Neonates: Post Hoc Analysis of a Randomized Clinical Trial

Effect of High-Dose Erythropoietin on Blood Transfusions in Extremely Low Gestational Age Neonates: Post Hoc Analysis of a Randomized Clinical Trial Effect of High-Dose Erythropoietin on Blood Transfusions in Extremely Low Gestational Age Neonates: Post Hoc Analysis of a Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) /jamapediatrics.2020.2271. Online ahead of print. Effect of High-Dose Erythropoietin on Blood Transfusions in Extremely Low Gestational Age Neonates: Post Hoc Analysis of a Randomized Clinical Trial , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Neonatology, Department of Pediatrics, University of Washington, Seattle. 2 Department of Biostatistics, University of Washington, Seattle. 3 now with Center for Clinical and Translational Research, Seattle Children's

2020 EvidenceUpdates

12. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination with Oseltamivir in Elderly and NonElderly Adults Hospitalized with Influenza A Infection: OPAL study Full Text available with Trip Pro

efficacy). Pimodivir is a first-in-class antiviral for influenza A under development for these patients. Methods: Hospitalized patients with influenza A infection were randomized 2:1 to receive pimodivir 600 mg plus oseltamivir 75 mg or placebo plus oseltamivir 75 mg twice daily for 7 days in this phase 2b study. The primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65-85 years) versus non-elderly adults (aged 18-64 years). Secondary endpoints included time-to-patient (...) -reported symptom resolution. Results: Pimodivir pharmacokinetic parameters in non-elderly and elderly patients were similar. Time-to-influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours). There was a lower incidence of influenza-related complications in the pimodivir group (7.9%) versus placebo group (15.6%). Treatment was generally well tolerated. Conclusions: No apparent relationship was observed between pimodivir pharmacokinetics and age. Our

2020 EvidenceUpdates

13. Abdominal aorta aneurysm (AAA) screening of men aged 65

Abdominal aorta aneurysm (AAA) screening of men aged 65 Abdominal aorta aneurysm (AAA) screening of men aged 65 - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Abdominal aorta aneurysm (AAA) screening of men aged 65 Order Download: Key message Abdominal aortic aneurysm (AAA) is a weakening of the aortic wall resulting in an abnormal (...) dilatation of the abdominal aortic artery. AAAs bears the risk of rupture, which is a dramatic emergency condition with a high risk of death. In Norway, about 1% of all deaths among men older than 65 years are caused by AAA rupture. The mortality rate due to AAA rupture is approximately 75%, with about half of the deaths occurring before the patient reaches the hospital. The larger the AAA, the higher is the risk of rupture. Prevalence of AAA among men varies across countries from approx. 1.5-3

2020 Norwegian Institute of Public Health

14. The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial

The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) : 10.1016/j.jen.2020.04.011. Online ahead of print. The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial , , , , , PMID: 32690314 DOI: Item in Clipboard The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial Duygu Sönmez Düzkaya et al. J

2020 EvidenceUpdates

15. Evidence review on the benefits of physical activity for older people

of developing functional limitations or a decline in Basic Activities of Daily Living (BADL) disability 14 15 was reduced Institute of Public Health 6 by participation in physical activity 15 . Emerging evidence also highlights the positive impact of physical activity on the healthy ageing process, by improving QoL and increasing the odds of maintaining wellbeing in older age 16 . Finally, as the global population ages, the number of people living with cognitive impairment or dementia is expected (...) 18 19 . Growing evidence also reports that physical activity can improve cognitive function and, consequently, delay the progression of cognitive impairment in older adults 14 20 21 . Implications for Research and Policy Physical activity plays a key role in healthy ageing across the life cycle but especially in later years in the management of one’s health and wellbeing. The goal of public health is to decrease the time spent in ill- health as people age and ensure that an increase in life

2020 Institute of Public Health in Ireland

16. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data Full Text available with Trip Pro

: alteplase; elderly; ischemic stroke; recombinant tissue-type plasminogen activator; thrombolysis. Figures Figure 1. 5 Estimated effect of alteplase vs… Figure 1. 13 Estimated effect of alteplase vs placebo on the odds of good stroke outcome… Figure 1. Estimated effect of alteplase vs placebo on the odds of good stroke outcome by time to treatment, patient age, and stroke severity. A , Time to treatment ( P =0.0203 for interaction). B , Patient age ( P =0.7383 for interaction). C , Stroke severity (...) JA, Lindsberg PJ, Ringleb PA, Wahlgren NG, Lees KR; VISTA Collaborators; SITS Collaborators Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010341c6046.doi: 10.1136/bmj.c6046 - - Show all 33 references Related information LinkOut - more resources Full Text Sources Research Materials Miscellaneous Full-text links [x] [x] Citation text Copy Download .nbib Format: Send To [x] Connect

2020 EvidenceUpdates

17. Effects of Whole-Body Vibration Training on the Physical Function of the Frail Elderly: An Open, Randomized Controlled Trial

Cite Abstract Objective: To investigate the feasibility and benefits of whole-body vibration (WBV) exercise as a safe and effective training tool for countering sarcopenia and age-related declines in mobility and function in the frail elderly. Design: An open, randomized controlled trial. Setting: Residential care facilities. Participants: Male and female volunteers (N=117; 82.5±7.9y). Interventions: After prescreening for contraindications, participants were randomly allocated to a control (...) Effects of Whole-Body Vibration Training on the Physical Function of the Frail Elderly: An Open, Randomized Controlled Trial Effects of Whole-Body Vibration Training on the Physical Function of the Frail Elderly: An Open, Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly

2020 EvidenceUpdates

18. Cost-effectiveness of a preventive self-care health management program for community-dwelling older adults: a randomised controlled trial

for community-dwelling older adults: a randomised controlled trial , , Affiliations Expand Affiliations 1 School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. 2 School of Optometry, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. PMID: 32638995 DOI: Item in Clipboard Cost-effectiveness of a preventive self-care health management program for community-dwelling older adults: a randomised controlled trial Arkers Kwan Ching Wong et al. Age Ageing . 2020 (...) provide some evidence to suggest that the addition of a home-based, preventive self-care health management program may have effects on cost outcomes for community-dwelling older adults in Hong Kong. Keywords: community-dwelling older adults; cost-effectiveness; self-care; self-efficacy. © The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. Similar articles Lewis H

2020 EvidenceUpdates

19. Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Addendum to Commission A19-70

with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This adjusted indirect comparison (see Figure 1) was used for the benefit assessment. In its dossier [2], the company had presented analyses for the outcomes “serious adverse events (SAEs)” and “discontinuation due to adverse events (AEs)”. The results of these outcomes contained events that can be both symptoms of the underlying disease (...) (IQWiG) - 2 - 2 Assessment The company had presented analyses on the basis of an indirect comparison (see Figure 1) in its dossier for the assessment of ivacaftor in combination with tezacaftor/ivacaftor in patients with CF aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. For the outcomes “SAEs” and “discontinuation due to AEs”, the company had shown analyses that contained events that form part of the symptoms of the underlying disease or that can be both side

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65

]. In its dossier [2], the pharmaceutical company (hereinafter referred to as “the company”) presented results of the randomized controlled trials (RCTs) VX08-770-102 and VX08-770-103 for the assessment of the added benefit of ivacaftor in the treatment of cystic fibrosis in patients aged 6 years and older and weighing 25 kg or more who have the G551D gating mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These studies were included in the benefit assessment (...) , and no information at all on prior and concomitant medication for the relevant subpopulation of the VX08-770-103 study. Hence, the certainty of conclusions of the study results was reduced both for conclusions on patients aged 12 years and older based on the VX08-770-102 study and for children between 6 and 11 years of age based on the VX08-770-103 study. In its comments, the company presented supplementary information on concomitant antibiotic treatment in the studies VX08-770-102 and VX08-770-103, which went

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)